Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aims: To investigate midlife cholesterol in relation to Alzheimer’s disease (AD) and vascular dementia (VaD) in a large multiethnic cohort of women and men. Methods: The Kaiser Permanente Northern California Medical Group (healthcare delivery organization) formed the database for this study. The 9,844 participants underwent detailed health evaluations during 1964–1973 at ages 40–45 years; they were still members of the health plan in 1994. AD and VaD were ascertained by medical records between 1 January 1994 and 1 June 2007. Cox proportional hazards models – adjusted for age, education, race/ethnic group, sex, midlife diabetes, hypertension, BMI and late-life stroke – were conducted. Results: In total, 469 participants had AD and 127 had VaD. With desirable cholesterol levels (<200 mg/dl) as a reference, hazard ratios (HR) and 95% CI for AD were 1.23 (0.97–1.55) and 1.57 (1.23–2.01) for borderline (200–239 mg/dl) and high cholesterol (≥240 mg/dl), respectively. HR and 95% CI for VaD were 1.50 (1.01–2.23) for borderline and 1.26 (0.82–1.96) for high cholesterol. Further analyses for AD (cholesterol quartiles, 1st quartile reference) indicated that cholesterol levels >220 mg/dl were a significant risk factor: HR were 1.31 (1.01–1.71; 3rd quartile, 221–248 mg/dl) and 1.58 (1.22–2.06; 4th quartile, 249–500 mg/dl). Conclusion: Midlife serum total cholesterol was associated with an increased risk of AD and VaD. Even moderately elevated cholesterol increased dementia risk. Dementia risk factors need to be addressed as early as midlife, before underlying disease(s) or symptoms appear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings in late-life cohorts vary, with some finding higher levels of cholesterol associated with a lower risk356 and others finding a higher risk for VaD.357”
In the citing paper
“there are several controllable risk factors including obesity [156,157], hyperlipidemia [158,159], hypertension [160,161,162,163], type 2 diabetes [164,165,166,167], and sedentary lifestyle [168] that can be addressed in an effort to decrease the risk of developing AD.”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [158]
In the citing paper
“Obesity,71–73 dyslipidemia,74–77 and high BP78,79 are also major contributors to vascular brain health.”
From Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association (2017) · cites this paper as [75]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722 · cited 1×
“significantly increased the risk of developing VaD 3 decades later. High cholesterol levels (≥240 mg/dl) tended to increase VaD risk as well, but the association did not reach statistical significance. One reason for this could be the small sample size of VaD (127 persons in total, 39 with high cholesterol).VaD repres…”
BackgroundKrieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654 · cited 1×
“The present study investigates further the cholesterol-dementia relationship by focusing on the 2 main dementia subtypes, AD and vascular dementia (VaD), in a larger Kaiser Permanente cohort with updated follow-up information. We also examined the full range of cholesterol values (not just high cholesterol, >240 mg/dl…”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“High midlife cholesterol has previously been shown to be a risk factor for dementia in the multiethnic cohort of women and men from the Kaiser Permanente Medical Care Program of Northern California [”
BackgroundSelf-citationKivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., & Tuomilehto, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70537-3 · Cited by 1,126 · cited 1×
“Although our cohort does not include persons with mixed dementia as recognized by ICD-9 CM, the concomitant presence of neurodegenerative and vascular pathologies in a portion of the sample cannot be excluded. Clinical Significance and ConclusionsPhysicians tend to confine AD and VaD to geriatric age borders, and addr…”
ResultSelf-citationSerum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645
Self-citationIribarren, C., Sidney, S., Sternfeld, B., & Browner, W. S. (2000) · JAMA · doi:10.1001/jama.283.21.2810 · Cited by 482
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 1×
“but no association was observed in the Honolulu Asia Aging Study (HAAS) or Framingham study [”
BackgroundCrossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain
BJÖRKHEM, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01725.x · Cited by 381
Cited by
Items 201–300 of 553
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 33
“that cholesterol levels >220 mg/dL were a significant risk factor for AD [1361].”
BackgroundLow Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease
Chen, Y. S., Lille YOD study group BomboisStéphanieDr. BoutantinJustine CassagnaudPascalineDr. ChenYaohuaDr. DelbeuckXavier DelmaireChristineDr. DeramecourtVincentProf. GelePatrick Houssein-FoucherClaudeDr. JacquemontCharlotte LebertFlorenceDr. LebouvierThibaudDr. LopezRenaud MackowiakMarie-AnneDr. MaureilleAurélien PasquierFlorenceProf. PetytGrégoryDr. PolletMarianne Rollin-SillaireAdelineDr. SchraenSusannaDr. SemahFranckProf. VanhoutteMatthieu, Sillaire, A. R., Dallongeville, J., Skrobala, E., Wallon, D., Dubois, B., Hannequin, D., & Pasquier, F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170367 · Cited by 35
“There was no difference between participants with dementia and controls in the prevalence of hypercholesterolemia, which is considered to be a risk factor for late-onset dementia [36].”
BackgroundPrecision Medicine for Alzheimer’s Disease Prevention
Berkowitz, C. L., Mosconi, L., Scheyer, O., Rahman, A., Hristov, H., & Isaacson, R. (2018) · Healthcare · doi:10.3390/healthcare6030082 · Cited by 32
“In addition to genetics, there are many other important aspects of a precision medicine approach to AD prevention, including medical comorbidities such as hypertension [70,71], diabetes [72], and hyperlipidemia [73,74], which have been associated with an increased risk of developing AD.”
BackgroundPathogenesis and Treatment of Vascular Cognitive Impairment
Jellinger, K. A. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.37 · Cited by 34
Mancini, G., Dias, C., Lourenço, C. F., Laranjinha, J. A. N., Bem, A. F. D., & Ledo, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210122 · Cited by 34
“Evidence from both clinical and pre-clinical studies indicate that lifestyle associated vascular risk factors including obesity [2], hypercholesterolemia [3], hypertension [4], atherosclerosis [5], and diabetes [6] play a critical role in development of AD.”
Benito‐León, J., Quiroga, S. V., Villarejo‐Galende, A., & Bermejo‐Pareja, F. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.016 · Cited by 35
“Epidemiological studies indicate that high midlife plasma total cholesterol levels increases the risk of Alzheimer's disease and vascular dementia [3,4], but decreasing total plasma cholesterol levels after midlife may reflect ongoing disease processes andmay represent a risk marker for late-life dementia [5–8].”
Role of LDL Cholesterol and Endolysosomes in Amyloidogenesis and Alzheimer’s Disease
Chen, X. (2014) · Journal of Neurology & Neurophysiology · doi:10.4172/2155-9562.1000236 · Cited by 30
Zhou, Z., Moran, C., Murray, A. M., Zoungas, S., Magnussen, C. G., Chong, T. T. ‐., Shah, R. C., Sheets, K. M., Nelson, M. R., Zhu, C., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000210247 · Cited by 29
Davis, G., Baboolal, N. S., Rae, A. M., & Stewart, R. J. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018288 · Cited by 30
Cholesterol Metabolism in Neurodegenerative Diseases
He, K., Zhao, Z., Zhang, J., Li, D., Wang, S., & Liu, Q. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0674 · Cited by 33
“High serum cholesterol in midlife appears to increase the risk of AD in later life, while high serum cholesterol in later life seems to decrease the risk of AD (Solomon et al., 2009; Mielke et al., 2005).”
George, K. M., Gilsanz, P., Peterson, R. L., Barnes, L. L., DeCarli, C. S., Mayeda, E. R., Mungas, D., & Whitmer, R. A. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab143 · Cited by 31
Self-citationCell non-autonomous regulation of cerebrovascular aging processes by the somatotropic axis
Bickel, M. A., Csik, B., Gulej, R., Ungvari, A., Nyul-Toth, A., & Conley, S. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1087053 · Cited by 29
Treatment of Vascular Cognitive Impairment
Ritter, A. R., & Pillai, J. A. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0367-0 · Cited by 30
Statins and Vascular Dementia: A Review
Giannopoulos, S., Katsanos, A. H., Kosmidou, M. S., & Tsivgoulis, G. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132366 · Cited by 27
Dysregulation of SREBP2 induces BACE1 expression
Mastrocola, R., Guglielmotto, M., Medana, C., Catalano, M. G., Cutrupi, S., Borghi, R., Tamagno, E., Boccuzzi, G., & Aragno, M. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.06.010 · Cited by 30
“Moreover, several studies report that alterations in both plasma and in brain cholesterol levels are related to AD (Kivipelto and Solomon, 2006; Puglielli et al., 2003; Simons et al., 2001; Solomon et al., 2009).”
Effects of Posttraumatic Stress Disorder and Metabolic Syndrome on Cognitive Aging in Veterans
Green, E., Fairchild, J. K., Kinoshita, L. M., Noda, A. M., & Yesavage, J. A. (2015) · The Gerontologist · doi:10.1093/geront/gnv040 · Cited by 28
de Souza, R. M., de Souza, L., Machado, A. E., Alves, A. C. D. B., Rodrigues, F. S., Aguiar, A. S., Santos, A. R. S., Bem, A. F. D., & Moreira, E. L. G. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.09.022 · Cited by 33
de Oliveira, J., Moreira, E. L. G., & Bem, A. F. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102149 · Cited by 27
Preventing Alzheimer’s: Our Most Urgent Health Care Priority
Sherzai, D., & Sherzai, A. Z. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827619843465 · Cited by 28
Martínez‐Cué, C., & Rueda, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186906 · Cited by 26
Kang, S., Kim, E., Cho, H., Kim, D. J., Kim, H. C., & Jung, S. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-16788-x · Cited by 34
Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline
Anderson, T., Sharma, S. K., Kelberman, M. A., Ware, C. B., Guo, N., Qin, Z. S., Weinshenker, D., & Parent, M. B. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15900 · Cited by 27
“After controlling for BMI, moderately elevated midlife cholesterol (200– 239 mg/dL) increases future AD incidence by 23%, and higher cholesterol levels increase AD inci - dence by 66% (Solomon et al., 2009).”
BackgroundMetaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?
Taga, M., Minett, T., Classey, J., Matthews, F. E., Brayne, C., Ince, P. G., Nicoll, J. A., Hugon, J., Boche, D., & CFAS, M. (2017) · Brain Pathology · doi:10.1111/bpa.12388 · Cited by 26
“MMSE at last assessment †† 25 (22-28) 14 (8-20) 11 (6-17)”
BackgroundGratuze, M., Julien, J., Morin, F., Calon, F., Hébert, S. S., Marette, A., & Planel, E. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.016 · Cited by 30
“Although age is the main risk factor of sporadic AD (Ritchie and Lovestone, 2002), epidemiological studies suggest that metabolic disorders, such as obesity, type 2 diabetes (T2D), high cholesterol, or coronary heart disease, are associated with a higher risk of AD later in life (Kivipelto et al., 2005; Newman et al.,…”
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Acidifying Endolysosomes Prevented Low-Density Lipoprotein-Induced Amyloidogenesis
Liang, H., Soliman, M. L., Geiger, N. H., Miller, N., Afghah, Z., Lakpa, K. L., Chen, X., & Geiger, J. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180941 · Cited by 29
“…disorder that is characterized clinically by progressive impairments in memory and cognition, and neuropathologically by loss of synaptic integrity, accumulations of amyloid-(cid:2) (A (cid:2) ) and levels of circulating cholesterol have been implicated in the pathogenesis of sporadic AD [8–12].”
Bliss, E. S., Biki, S. M., Wong, R. H. X., Howe, P. R. C., & Mills, D. E. (2023) · European Journal of Applied Physiology · doi:10.1007/s00421-023-05154-y · Cited by 25
“Additionally, reductions in cerebrovascular function and structure are largely attributed to modifiable risks factors that impact on cardiometabolic health, particularly physical inactivity (Ahtiluoto et al. 2010; Anstey et al. 2014; Bunch et al. 2010; Kalmijn et al. 2002; Kokmen et al. 1996; Kuller et al. 2005; Prins…”
BackgroundZhao, Y., Zhang, H., Cheng, J., Zou, Y., Zhang, D., & Duan, X. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2302040 · Cited by 29
The CAIDE Dementia Risk Score and the Honolulu-Asia Aging Study
Chosy, E. J., Edland, S. D., Gross, N., Meyer, M., Liu, C. Y., Launer, L. J., & White, L. R. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000504801 · Cited by 26
Alzheimer's disease knowledge among American Indians and Alaska Natives
Jernigan, M., Boyd, A. D., Noonan, C., & Buchwald, D. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12101 · Cited by 26
Hypercholesterolemia and the Increased Risk of Vascular Dementia: a Cholesterol Perspective
Shang, G., Shao, Q., Lv, K., Xu, W., Ji, J., Fan, S., Kang, X., Cheng, F., Wang, X., & Wang, Q. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01217-3 · Cited by 26
“A series of clinical studies have demonstrated an association between high cholesterol levels in midlife and an increased risk of dementia [15, 16], whereas elevated late-life serum cholesterol may be associated with a reduced risk of VaD [17].”
Rodrigues, M. S., de Paula, G. C., Duarte, M. B., de Rezende, V. L., Possato, J. C., Farias, H. R., Medeiros, E. B., Feuser, P. E., STRECK, E. L., Machado‐de‐Ávila, R. A., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111608 · Cited by 26
Advances in Vascular Cognitive Impairment
Gorelick, P. B., & Bowler, J. V. (2010) · Stroke · doi:10.1161/strokeaha.109.569921 · Cited by 23
Uemura, K., Doi, T., Shimada, H., Makizako, H., Yoshida, D., Tsutsumimoto, K., Anan, Y., & Suzuki, T. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000343486 · Cited by 27
Xiu-juan, W., Liu, Q., Zhang, Z., Xue, R., Li, P., & Li, B. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.179059 · Cited by 24
“…common risk factors with stroke e.g., hypertension (Qiu et al., 2005; Paglieri et al., 2008), diabetes (Araki, 2010; Fei et al., 2013), hyperlipemia (Purandare, 2009; Solomon et al., 2009), smoking (Mazzone et al., 2010; Gons et al., 2011), and drinking (Lobo et al., 2010; Weyerer et al., 2011).”
BackgroundRogne, S., Vangberg, T. R., Eldevik, P., Wikran, G., Mathiesen, E. B., & Schirmer, H. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000450885 · Cited by 26
Dunk, M. M., Driscoll, I. F., & Initiative, A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215091 · Cited by 29
Simvastatin Treatment Preserves Synaptic Plasticity in AβPPswe/PS1dE9 Mice
Métais, C., Brennan, K., Mably, A. J., Scott, M., Walsh, D. M., & Herron, C. E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130257 · Cited by 27
“High cholesterol levels in 635 midlife are reported to be a risk factor for the devel636 opment of AD [63].”
Dolan, C., Glynn, R. W., & LAWLOR, B. A. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.01.004 · Cited by 23
Fiocco, A. J., Krieger, L., D’Amico, D., Parrott, M. D., Laurin, D., Gaudreau, P., Greenwood, C., & Ferland, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.04.008 · Cited by 21
Lefèvre‐Arbogast, S., Wagner, M., Proust‐Lima, C., & Samieri, C. (2019) · Current Nutrition Reports · doi:10.1007/s13668-019-00285-1 · Cited by 23
Statins for vascular dementia: A hype or hope
Raja, H. G., Al-Kuraishy, H. M., Shokr, M. M., Al-Gareeb, A. I., Al‐Harchan, N. A., Alruwaili, M., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.059 · Cited by 21
“Moreover, mid-life hypercholesterolemia is associated with high risk for the development of AD and VaD in late life (Solomon et al., 2009) .”
Lim, F. T., Lim, S. M., & Ramasamy, K. (2017) · Food & Function · doi:10.1039/c7fo00764g · Cited by 25
Vascular neurocognitive disorders and the vascular risk factors
Albu, C. V., Pădureanu, V., Boldeanu, M. V., Bumbea, A. M., Enescu, A. Ş., Albulescu, D. M., Siloşi, C. A., & Enescu, A. (2018) · Journal of Mind and Medical Sciences · doi:10.22543/7674.51.p715 · Cited by 23
“as: hypertension (41), dyslipidemia (42), DM (43),”
Rosa, G., Giannotti, C., Martella, L. A., Massa, F., Serafini, G., Pardini, M., Nobili, F. M., & Monacelli, F. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191075 · Cited by 24
Incident Atrial Fibrillation and Risk of Dementia in a Diverse, Community‐Based Population
Bansal, N., Zelnick, L. R., An, J., Harrison, T. N., Lee, M. S., Singer, D. E., Fan, D., & Go, A. S. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028290 · Cited by 21
Vascular risk factors in Alzheimer's disease — Preliminary report
Stefanova, E. D., Pavlovic, A. M., Jovanović, Z., Veselinovic, N., Despotovic, I., Stojković, T., Šternić, N., & Kostić, V. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.065 · Cited by 23
“Midlife serum total cholesterol was associated with an increased risk of AD and VaD; and evenmoderately elevated cholesterol increased dementia risk [25].”
BackgroundHawkins, K. A., Emadi, N., Pearlson, G. D., Winkler, A. M., Taylor, B. A., Dulipsingh, L., King, D., Pittman, B. P., & Blank, K. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-9980-9 · Cited by 21
Spielberg, J. M., Sadeh, N., Leritz, E. C., McGlinchey, R. E., Milberg, W., Hayes, J. P., & Salat, D. H. (2017) · Human Brain Mapping · doi:10.1002/hbm.23587 · Cited by 23
“For example, higher total serum (blood) cholesterol (TC) in mid-life predicts worse late-life cognitive capacity [Solomon et al., 2009].”
BackgroundSaeed, K. M., Shah, S. A., Ullah, R., Alam, S. I., Park, J. S., Saleem, S., Jo, M. H., Kim, M. W., Hahm, J. R., & Kim, M. O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9523758 · Cited by 24
“There is a wealth of literature from epidemiological [64], clinical, and laboratory studies, suggesting the role of cholesterol metabolism in modulating APP processing promoting AD pathogenesis [65], but very little is known about the Aβ effect on modifying cellular cholesterol metabolism leading to neurodegeneration.”
BackgroundRetractedRetinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles
Sen, M., Al-Amin, M., Kicková, E., Sadeghi, A., Puranen, J., Urtti, A. O., Caliceti, P., Salmaso, S., Arango‐González, B., & Ueffing, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.039 · Cited by 20
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence
Kazibwe, R., Rikhi, R. R., Mirzai, S., Ashburn, N. P., Schaich, C. L., & Shapiro, M. D. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01255-x · Cited by 22
“Although midlife hypercholesterolemia is associated with an increased risk of VaD [6, 72], late-life hypercho-lesterolemia, on the contrary, may have a protective effect [73 ].”
Peterson, R. L., George, K. M., Gilsanz, P., Ackley, S. F., Mayeda, E. R., Glymour, M. M., Mungas, D., DeCarli, C. S., & Whitmer, R. A. (2021) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000436 · Cited by 20
Self-citationCognitive and neuroimaging markers for preclinical vascular cognitive impairment
Lowry, E., Puthusseryppady, V., Johnen, A.-K., Renoult, L., & Hornberger, M. (2021) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2021.100029 · Cited by 23
Wang, Z.-T., Fu, Y., Zhang, Y.-R., Chen, S.-D., Huang, S., Liu, Y., Li, H., Ou, Y., Feng, J., Dong, Q., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02269-2 · Cited by 21
Hassen, C. B., Machado‐Fragua, M. D., Landré, B., Fayossé, A., Dumurgier, J., Kivimäki, M., Sabia, S., & Singh‐Manoux, A. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13140 · Cited by 21
Chaiyo, S., Kunpatee, K., Kalcher, K., Yakoh, A., & Pungjunun, K. (2024) · ACS Measurement Science Au · doi:10.1021/acsmeasuresciau.4c00012 · Cited by 20
Coronary artery disease in patients with dementia
Fowkes, R., Byrne, M. H. V., Sinclair, H., Tang, E. Y. H., & Kunadian, V. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000377 · Cited by 22
Kuang, Z.-M. (2020) · Cardiology Research and Practice · doi:10.1155/2020/1484357 · Cited by 22
Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOE ɛ4 Status
Pillai, J. A., Kou, L., Bena, J., Penn, L., & Leverenz, J. B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201609 · Cited by 22
“Hypercholesterolemia has beenreportedasahigh-riskfactorinmidlifemeasure-ments[15,19–23]andstrikinglyaslowriskinlatelife measurementsimpactingdementiaonset[23–25],but thecontributionfrom APOE (cid:2) 4 genotype in these findings is still debated.”
Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia
Moreira, E. L. G., Aguiar, A. S., de Carvalho, C. R., Santos, D. B., de Oliveira, J., Bem, A. F. D., Xikota, J. C., Walz, R., Farina, M., & Prediger, R. D. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.02.043 · Cited by 20
Mild cognitive impairment (MCI) and dementia in a sample of adults in the city of Bogotá
Pedraza, O. L., Salazar, A. M., Sierra, F., Montalvo, M. C., Muñoz, Y., Díaz, J. M., Lozano, A. G., & Piñeros, C. (2017) · Dementia & Neuropsychologia · doi:10.1590/1980-57642016dn11-030008 · Cited by 26
Association between Age at Diagnosis of Hyperlipidemia and Subsequent Risk of Dementia
Pan, Y., Liang, J., Zhang, W., Gao, D., Li, C., Xie, W., & Zheng, F. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.01.029 · Cited by 20
Norton, M. C., Clark, C. J., Tschanz, J. T., Hartin, P. J., Fauth, E. B., Gast, J. A., Dorsch, T. E., Wengreen, H. J., Nugent, C., Robinson, W. D., et al. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.05.001 · Cited by 25
“Midlife health has implications for later dementia as obesity [12], hypertension [13], and serum cholesterol [14] have been linked to higher dementia risk in late life.”
BackgroundVascular Contributions to Cognitive Impairment in Late Life
Chui, H. C., & Gomez, L. A. R. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.007 · Cited by 20
Outcome age‐based prediction of successful cognitive aging by total cholesterol
Silverman, J. M., & Schmeidler, J. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.01.009 · Cited by 22
Silverman, J. M., & Schmeidler, J. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.10.022 · Cited by 18
Han, K., & Kim, S. J. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5410 · Cited by 19
Cholesterol and Copper Affect Learning and Memory in the Rabbit
Schreurs, B. G. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/518780 · Cited by 18
Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives
Korábečný, J., Zemek, F., Soukup, O., Špilovská, K., Musílek, K., Jun, D., Nepovimová, E., & Kuča, K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50001-5 · Cited by 22
NHG-Standaard Dementie (derde herziening)+
van Charante, E. P. M., Perry, M., Vernooij-Dassen, M. J. F. J., Boswijk, D., Stoffels, J., Achthoven, L., & Luning-Koster, M. N. (2012) · Cited by 21
Foidl, B. M., & Humpel, C. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.01.009 · Cited by 17
de Leeuw, F. A., Tijms, B. M., Doorduijn, A. S., Hendriksen, H. M. A., van de Rest, O., de van der Schueren, M. A. E., Visser, M., van den Heuvel, E. G. H. M., van Wijk, N., Bierau, J., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12120 · Cited by 20
Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective
Jurcău, A., & Simion, A. (2021) · Medicina · doi:10.3390/medicina57060616 · Cited by 17
“Indeed, observational studies have documented an association between elevated levels of serum total and LDL-cholesterol and amyloid deposition [56] and increased risk of stroke and dementia [57].”
BackgroundAzab, E. F. E., & Abdulmalek, S. A. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4812993 · Cited by 17
“Furthermore, a lipid profile with high levels of low-density lipoprotein (LDL) cholesterol and low levels of high-density lipoprotein (HDL) cholesterol is linked to an increased risk of AD [16].”
BackgroundCirculating biomarkers that predict incident dementia
Weinstein, G., & Seshadri, S. S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt235 · Cited by 17
“When measured in midlife, substantial evidence supports an association between total cholesterol and dementia risk [19-22], although some studies did not find such an association [23-26].”
BackgroundDiabetes of the Brain: Computational Approaches and Interventional Strategies
Narasimhan, K., Meenakumari, G., Gauthaman, K., Kamal, M. A., Abuzenadeh, A. M., Al-Qahtani, M., & Kanagasabai, R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660156 · Cited by 17
“Blood cholesterol levels between 249 and 500 mg were highly prone to develop AD than levels below 200 mg [58].”
BackgroundAssociation of genetic polymorphisms of claudin‐1 with small vessel vascular dementia
Srinivasan, V., Braidy, N., Xu, Y. H., Xie, P., Kancherla, K., Chandramohan, S., Chan, E. K. W., & Chan, D. K. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12747 · Cited by 16
Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer’s disease patients
Costa, A. C., Joaquim, H. P. G., Nunes, V. S., Kerr, D. S., Ferreira, G. S., Forlenza, O. V., Gattaz, W. F., & Talib, L. L. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0838-2 · Cited by 16
“On the periphery, elevated cholesterol has been proposed to be a risk factor to developing AD by animal models and in vitro studies [61, 62].”
Ofori‐Asenso, R., Ilomäki, J., TACEY, M. A., Curtis, A. J., Zomer, E., Bell, J. S., Zoungas, S., & Liew, D. (2018) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317518787314 · Cited by 18
Cerebral amyloid angiopathy: a narrative review
Noto, N. M., Speth, R. C., & Robison, L. S. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1632252 · Cited by 17
Alzheimer’s disease: Pathophysiology and dental pulp stem cells therapeutic prospects
Xiong, W., Liu, Y., Zhou, H., Jing, S., He, Y., & Ye, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999024 · Cited by 17
“, 2018), high cholesterol (Solomon et al., 2009) and diabetes”
Cardiovascular Risk and Hippocampal Thickness in Alzheimer’s Disease
Donix, M., Scharf, M., Marschner, K., Werner, A., Sauer, C., Gerner, A., Nees, J. A., Meyer, S., Donix, K. L., von Kummer, R., et al. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/108021 · Cited by 16
“Midlife cholesterol levels influence the development of Alzheimer’s disease later in life, also possibly involving mechanisms other than the vascular pathway [12].”
BackgroundLi, R., Xu, D.-E., & Ma, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.005 · Cited by 17
“14 (Chen and Fernandez, 2001; Burns and Duff, 2002; Wolozin, 2002; Solomon et al., 2009; Di Paolo and Kim, 2011), which is pathologically characterized by extracellular senile plaques consisting of aggregated amyloid-b (Ab) peptides and intracellular neurofibrillary tangles (NFTs) containing…”
BackgroundLin, J. H. X., de Rezende, V. L., da Costa, M. D. A., de Oliveira, J., & Gonçalves, C. L. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173522 · Cited by 22
Li, L., Xiao, N., Yang, X., Gao, J., Ding, J., Wang, T., Hu, G., & Xiao, M. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.024 · Cited by 17
Vascular cognitive impairment (VCI): Progress towards knowledge and treatment
Legge, S. D., & Hachinski, V. (2010) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642010dn40100002 · Cited by 19
Effects of Walnut Polyphenol on Learning and Memory Functions in Hypercholesterolemia Mice
Shi, D., Chen, C., Zhao, S., Ge, F., Liu, D., & Song, H. (2014) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-2-8-4 · Cited by 19
“This is supported by studies in vivo, which confirm a potential beneficial protecting effect via inhibiting the cholesterol synthesis and lowering the concentrations of cholesterol against memory impairments [6,7].”
BackgroundPappolla, M. A., Refolo, L. M., Sambamurti, K., Zambón, D., & Duff, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240388 · Cited by 18
“One of these studies examined a multiethnic cohort comprising 9,844 participants who underwent detailed health evaluations at ages 40–45 [7].”
Meco, A. D., Jelínek, J., Lauretti, E., Curtis, M. E., Issa, J. J., & Praticò, D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0489-y · Cited by 15
Moazzami, K., Power, M. C., Gottesman, R. F., Mosley, T. H., Lutsey, P. L., Jack, C. R., Hoogeveen, R. C., West, N. A., Knopman, D. S., & Alonso, Á. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117324 · Cited by 14
Clark, C., Gholam‐Rezaee, M., Zullo, L., Kerksiek, A., Castelao, E., von Gunten, A., Preisig, M., Lütjohann, D., & Popp, J. (2022) · iScience · doi:10.1016/j.isci.2023.106740 · Cited by 14
“These findings are in line with several previous reports relating high circulating cholesterol levels with higher risk of cognitive decline in the general population.(27,28) Moreover, lower concentrations of HDL-cholesterol were associated with cognitive impairment at baseline.”
ResultRamdane, S., & Daoudi‐Gueddah, D. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511414552 · Cited by 14
Gao, P., Liu, R., Jin, Q., & Wang, X. (2021) · Food Bioscience · doi:10.1016/j.fbio.2021.101436 · Cited by 13
Different effects of CYP27A1 and CYP7B1 on cognitive function: Two mouse models in comparison
Goikolea, J., Latorre‐Leal, M., Tsagkogianni, C., Pikkupeura, S., Gulyás, B. Z., Cedazo-Mínguez, Á., Loera‐Valencia, R., Björkhem, I., Rodriguez‐Rodriguez, P., & Maioli, S. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106387 · Cited by 13
Prospective study on association between plasma amyloid beta-42 and atherosclerotic risk factors
Blasko, I., Kemmler, G., Jungwirth, S., Wichart, I., Weissgram, S., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0599-4 · Cited by 13
“The lack of consensus regarding the association between total cholesterol (TC) and AD was explained by the hypothesis that only midlife elevation in TC may be a risk factor for AD (Solomon et al. 2009), and that cholesterol control may be generally most salient for cognitive health in the young–old age period (Reynold…”
BackgroundCHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY.
Nicholson, A. M., & Ferreira, A. (2010) · PubMed · Cited by 15
Contu, L., Carare, R. O., & Hawkes, C. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12556 · Cited by 13
Cholesterol in midlife increases the risk of Alzheimer's disease during an up to 43-year follow-up
Rantanen, K. K., Strandberg, A. Y., Pitkälä, K. H., Tilvis, R. S., Salomaa, V. V., & Strandberg, T. E. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2014.05.002 · Cited by 13
Dutta, S., Rahman, S., Ahmad, R., Kumar, T., Dutta, G., Banerjee, S., Abubakar, A. R., Rowaiye, A. B., Dhingra, S., Ravichandiran, V., et al. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.2003705 · Cited by 12
“Furthermore, Solomon et al. 2009 reported that high serum cholesterol levels increase the risk of AD in middle age [29].”
Background
Metadata
- Authors
- Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A.
- Affiliations
- University of Eastern Finland (FI)
- Boston University (US)
- Kaiser Permanente (US)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 28
- Issue
- 1
- Pages
- 75-80
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC2814023
- OpenAlex
- W2134458253
- Cited by
- 557
- References
- 22
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 36 · 2023: 25 · 2022: 31 · 2021: 42 · 2020: 31 · 2019: 34 · 2018: 37 · 2017: 32 · 2016: 39 · 2015: 27 · 2014: 41 · 2013: 39 · 2012: 42
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kaiser Permanente
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK066308, DK066308)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, vascular dementia, dementia risk factors, total cholesterol, hypercholesterolemia, multi-ethnic cohort, men and women
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cholesterol, Data Interpretation, Statistical, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Socioeconomic Factors, Dementia, Vascular, Cohort Studies, Proportional Hazards Models, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.